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M utationsinleucine-richrepeatkinase2(LRRK2)arethemostfrequentcauseofgeneticParkinsondisease(PD),accounting for at least 4% of autosomal dominant
forms of familial PD and 1% of sporadic PD worldwide.1 The
LRRK2geneencodesa largemultidomainprotein that includes
anenzymaticallyactivecentral regionsurroundedbyaseriesof
putativeprotein-protein interactiondomains.2Disease-causing
mutationsareconcentratedwithin thecentral regionof thepro-
tein,which contains anROCGTPase domain, a COR sequence,
and a serine/threonine kinase domain. Thus far, at least 8mu-
tations(p.N1437H,p.R1441C/G/H,p.Y1699C,p.G2019S,p.I2020T,
andpossiblyp.I1371V)areconsideredtobepathogenic.p.G2019S
is themost frequentmutation but penetrance of p.G2019S and
other pathogenic LRRK2mutations is incomplete.3-5
TheclinicalpresentationofmanifestingLRRK2mutationcar-
riers tendstobe indistinguishable fromthatofsporadicPD,with
meanageatonsetofapproximately60yearsandappreciable re-
sponseto levodopa.6Conversely, theneuropathological features
canbeatypical forPDandheterogeneousevenwithinkindreds.7
In particular, autopsy studies have revealed that Lewy bodies
(LBs),whichare large intraneuronalproteinaggregatesconsist-
ing primarily of α-synuclein,8 are absent in a significant subset
of cases. This was a surprising finding because LBs are neuro-
pathological hallmarks of PD thought to be central to the neu-
rodegenerative process and the clinical expression of PD and
other synucleinopathies. Here we investigated the correlation
ofclinical featureswithLBpathology inLRRK2-relatedPD.This
mayprovide insight into the relationshipbetweenα-synuclein
pathology and specific features of the PD symptom complex.9
Methods
All publishedLRRK2-related autopsy casesup toOctober 2013
were identified by searching for English language articles in
PubMed. The search terms LRRK2, Lewy body/bodies, pathol-
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ogy/pathological,neuropathology/neuropathological, and/orau-
topsy/autopsieswere used. Additional articles were found by
searching the reference lists of identified articles and the au-
thors’ own files. Authors of published cases and directors of
brain banks were contacted to identify unpublished cases.
Clinical data were extracted from published articles. Addi-
tional data were obtained by requesting that investigators
complete a clinical data form (eFigure in the Supplement) if
the patient’s clinic record was available. Neuropathological
data were extracted from published articles and/or pathol-
ogy reports when available. Cases were excluded if the asso-
ciated LRRK2 mutation was not one of the putative patho-
genic mutations (previously mentioned), the patient did not
have a clinical diagnosis of PD, or there was minimal or no
available clinical and/or pathological information. Epi Info 7
from the Centers for Disease Control and Prevention was
used for data analysis (www.cdc.gov/epiinfo/). Categorical
variables were compared using the Fisher exact test. Con-
tinuous variables were compared using the t test. Logistic
regression was performed to adjust for disease duration and
age at death. Adjustment for Alzheimer disease–related
pathology was made, where indicated, using Braak neurofi-
brillary tangle stage, which was estimated from the avail-
able data and dichotomized (≤stage III and ≥ stage IV).
When necessary, a flattening constant of 1 was added to
each cell to allow an odds ratio to be calculated. No imputa-
tion was made for missing data; patients missing values on
an outcome were not included in the analysis for that out-
come. Because this was an exploratory study, no adjust-
ments were made for multiple comparisons. Separate analy-
ses were also performed for p.G2019S-only cases. The study
was approved by the ethics board of the University Health
Network, Toronto, Ontario, Canada.
Results
Fifty-nine autopsy cases with LRRK2 variants were identi-
fied: 54 published and 5 unpublished cases. Twenty-two
cases were excluded from the analysis: 3 with nonpatho-
genic variants; 2 nonmanifesting LRRK2 mutation carriers
without a clinical diagnosis of PD; and 17 with insufficient
clinical and/or pathological data (eTable 1 in the Supple-
ment). No cases were excluded for neurological disease
other than PD. Thirty-seven LRRK2-related PD cases were
included: 33 published and 4 unpublished cases (17 with
LBs and 20 without LBs) (eTable 2 in the Supplement). Neu-
ronal loss within the substantia nigra was reported for all of
these cases except for 2, in which these data were not pro-
vided. There were very limited data on neuronal loss within
other brain regions. The demographic and genetic features
of all included cases are summarized in Table 1. All cases
with a p.I2020T mutation were of Japanese ethnicity. Cases
with or without LBs were similar with respect to sex, dis-
ease duration, and age at death. Cases with LBs were more
likely to have a p.G2019S mutation. The demographic fea-
tures of p.G2019S cases (11 with LBs and 6 without LBs) are
summarized in Table 2.
Table 3 provides a summary of the frequency of clinical
features in LRRK2 cases with or without LBs. Tremor was
the most common presenting symptom for LRRK2 patients
regardless of the presence of LBs (65% for both groups). Car-
dinal motor symptoms, atypical features, levodopa respon-
siveness, and motor complications (see eFigure in the
Supplement for details) occurred with similar frequency in
both groups for all LRRK2 cases and for the subset of
p.G2019S cases. Certain nonmotor features (documented on
history and/or examination) were more frequent among
LRRK2 cases with LBs. After adjusting for disease duration
and age at death, cognitive impairment/dementia, anxiety,
and orthostatic hypotension were associated with the pres-
ence of LBs (Table 4). Cognitive impairment/dementia and
Table 1. Demographic and Genetic Features of all LRRK2 Cases
With andWithout LB Pathology
Feature
With LBs
(n = 17)
Without LBs
(n = 20)
P
Value
Male, % (no./No.) 23.5 (4/17) 40.0 (8/20) .32
Race/ethnicity
Non-Asian, % (no./No.) 92.9 (13/14) 57.9 (11/19) .05
White non-Jewish, No. 10 10
Ashkenazi Jewish, No. 3 1
Asian, % (no./No.) 7.1 (1/14) 42.1 (8/19)
Age at onset, mean (SD), y 56.0 (11.2) 61.0 (10.2)a .17
Disease duration, mean (SD), y 19.2 (9.0) 16.2 (6.7) .27
Age at death, mean (SD), y 75.2 (9.3) 77.2 (8.4) .49
LRRK2mutation
p.G2019S, % (no./No.) 64.7 (11/17) 30.0 (6/20) .05
Other, % (no./No.) 35.3 (6/17) 70.0 (14/20)
p.I2020T, No. 1 8
p.R1441C, No. 2 2
p.R1441G, No. 0 2
p.Y1699C, No. 1 2
p.N1437H, No. 1 0
p.I1371V, No. 1 0
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
a Seventeen of 20 cases.
Table 2. Demographic Features of LRRK2 p.G2019S Cases
With andWithout LB Pathology
Feature
With LBs
(n = 11)
Without LBs
(n = 6)
P
Value
Male, % (no./No.) 36.4 (4/11) 50.0 (3/6) .64
Race/ethnicity
Ashkenazi Jewish, % (no./No.) 37.5 (3/8) 20.0 (1/5) >.99
White non-Jewish, % (no./No.) 62.5 (5/8) 80.0 (4/5)
Asian, % (no./No.) 0 (0/8) 0 (0/5)
Age at onset, mean (SD), y 57.0 (12.8) 68.0 (7.5) .07
Disease duration, mean (SD), y 21.1 (9.7) 13.5 (4.2) .09
Age at death, mean (SD), y 78.1 (6.6) 81.5 (4.1) .27
Family history of PD, % (no./No.)a 50.0 (5/10) 60.0 (3/5) >.99
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
a At least 1 first-, second-, and/or third-degree relative with PD.
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anxiety were also associated with the presence of LBs
within the subgroup of cases with the p.G2019S mutation.
The association between cognitive impairment/dementia
and the presence of LBs was maintained after adjustment
for the degree of Alzheimer disease–related pathology (odds
ratio, 8.14; 95% CI, 1.46-45.47; P = .02 for all LRRK2 cases
and odds ratio, 76.03; 95% CI, 1.07-5414.76; P = .047 for only
p.G2019S cases).
Discussion
Toourknowledge, this study is the first report of clinicopatho-
logical correlations in a series of LRRK2-related PD cases. We
found that a primarily motor phenotype was associated with
an absence of LBs. Parkinsonism (ie, bradykinesia plus rigid-
ity, tremor, and/or postural instability) occurring indepen-
dently of LB pathology has also been observed in the context
ofmutations inPARK2,whichencodesparkin,wheremost au-
topsy reports describe an absence of LBs.10 Conversely, LBs
have been detected in the brains of peoplewithout themotor
featuresofPD, anentity termed incidentalLBdisease.Our find-
ings are consistent with these observations that LBs are nei-
ther necessarynor sufficient for the clinical expressionof par-
kinsonism.Yet, there is strongevidence inexperimentalmouse
models of PD that accumulation of α-synuclein aggregates in
thesubstantianigrapars compacta is associatedwith thedeath
of dopaminergic neurons that harbor these aggregates with
concomitant loss of tyrosine hydroxylase and dopamineme-
tabolites in thedorsal striatum.11There is similar evidence link-
ing α-synuclein aggregates in hippocampus to hippocampal
neuron loss andcognitive impairment.12 It is proposed that the
neuropathological correlate of parkinsonian motor features
is neuronal loss in the ventrolateral tier of the substantia
nigra pars compacta.8 However, loss of nigral neurons is
also not specific for a diagnosis of PD because it occurs in
many other neurodegenerative disorders with prominent
parkinsonism such as progressive supranuclear palsy and
multiple system atrophy.
The expression of nonmotor features in this series of
LRRK2-related PD cases was found to be related to the pres-
ence of LBs. In particular, cognitive impairment/dementia,
anxiety, and orthostatic hypotension were more likely to
occur at some point during the disease course in patients
who were found to have LBs at autopsy. Many nonmotor
features tend to occur with longer disease duration and/or
older age13 but we did not find that these potential con-
founders accounted for the differences observed between
those with or without LBs. Evidence for an association
between Lewy pathology and nonmotor symptoms has
been previously demonstrated for cognitive impairment in
PD. In particular, several studies have demonstrated a
Table 3. Frequency of Clinical FeaturesWith orWithout LB Pathologya
Feature
All LRRK2 Cases
(N = 37)
LRRK2 p.G2019S Cases
(n = 17)
With LBs
(n = 17)
Without LBs
(n = 20) P Value
With LBs
(n = 11)
Without LBs
(n = 6) P Value
Motor features, % (no./No.)
Bradykinesia 100 (17/17) 100 (18/18) >.99 100 (11/11) 100 (5/5) >.99
Rigidity 100 (17/17) 100 (15/15) >.99 100 (11/11) 100 (6/6) >.99
Tremor 94 (16/17) 94 (16/17) >.99 91 (10/11) 100 (6/6) >.99
Postural instability 100 (16/16) 92 (12/13) .45 100 (11/11) 80 (4/5) .31
Atypical features 17 (2/12)b,c 33 (3/9)d .61 11 (1/9)c 0 (0/3) >.99
Nonmotor features, % (no./No.)
Cognitive impairment/dementia 67 (10/15) 20 (4/20) .01 82 (9/11) 17 (1/6) .03
Depression 79 (11/14) 38 (3/8) .08 89 (8/9) 67 (2/3) .45
Anxiety 82 (9/11) 0 (0/7) .002 100 (8/8) 0 (0/3) .006
Orthostatic hypotension 50 (6/12) 0 (0/13) .005 63 (5/8) 0 (0/3) .18
Urinary symptoms 40 (4/10) 25 (3/12) .65 57 (4/7) 0 (0/2) .44
Constipation 78 (7/9) 38 (5/13) .10 100 (6/6) 100 (2/2) >.99
Levodopa treatment, % (no./No.)
Positive responsee 80 (8/10)f 86 (12/14)g >.99 71 (5/7) 60 (3/5)g >.99
Fluctuations 67 (10/15) 80 (12/15) .68 64 (7/11) 67 (4/6) >.99
Dyskinesia 73 (11/15) 62 (8/13) .69 80 (8/10) 50 (3/6) .30
Maximum levodopa dose, mean (SD), mg 798 (431) 836 (504) .85 741 (395) 840 (391) .67
No. of cases 10 11 8 5
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
a The results for the features in bold are statistically significant.
bOne patient had supranuclear gaze palsy.
c One patient had upper motor neuron signs andmyoclonus.
dOne patient had upper motor neuron signs, 1 patient had supranuclear gaze
palsy and upper motor neuron signs, and 1 patient had amyotrophy.
e Percentage of patients with moderate to marked levodopa response.
f One patient did not have a trial of levodopa.
g One patient could not tolerate levodopa.
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strong correlation between dementia and severity of cortical
Lewy pathology.14-16
Based on our findings, we hypothesize that LRRK2-
related PDwith LBs is associatedwithmore extensive neuro-
degeneration whereas neuronal loss may be more restricted
(eg, to the substantianigrapars compacta) in cases lackingLBs.
This would be similar to parkin-related PD in which there is
frequently an absence of LBs, restricted neurodegeneration,
anda relative lackofnonmotor features.10 Inpatientswithspo-
radicPD, corticalLewypathologycorrelateswithdementiabut
Alzheimerdiseaseplaques and tangles also contribute to their
cognitive impairment.16,17 It is possible that aggregates of pro-
teinsother thanα-synuclein are contributors to the clinical ex-
pression of LRRK2-related PD. Standardized neuropathologi-
cal assessments of a series of LRRK2 autopsy cases, including
semiquantitativemeasures of neuronal loss and examination
of various protein aggregates in brain stem, subcortical, and
cortical structures, are needed to further interrogate correla-
tionswith specificmotor andnonmotor symptoms inLRRK2-
related PD.
Prior reports have highlighted the occurrence of atypical
neuropathological findings at autopsy for some manifesting
LRRK2mutation carriers includingpathology resemblingpro-
gressive supranuclear palsy,multiple systematrophy, or fron-
totemporal lobar degenerationwith ubiquitin-positive inclu-
sions, presence of TDP-43 inclusions, and/or lack of LB
pathology (eTable 2). Our assessment was limited to clinical
correlations with LBs because this was the only neuropatho-
logical feature available for all cases. Additional details—such
as the presence of α-synuclein immunoreactive inclusions in
neuronal processes (eg, Lewyneurites, dotlike structures, and
axonal spheroids), degreeofneuronal loss, involvementof ex-
tranigral structures, immunostaining results for other pro-
tein inclusions, andthedistributionof these features—wereun-
available for many cases so analysis of these other features
could not be carried out here. Furthermore, there is a lack of
standard operating procedures for the neuropathological di-
agnosis of PD8 and methodological differences (eg, areas
sampled, immunostaining performed, and types of antibod-
iesused) among thedifferent centersmayhaveproducedvari-
able results. Ongoing and future efforts to standardize au-
topsycollection,handling, and reporting forLRRK2-relatedPD
caseswill help toprovidedata formoredetailed clinicopatho-
logical correlations.
The LRRK2 autopsy cases used in this study were identi-
fied primarily from published reports; therefore, there is the
potential for ascertainmentbias. Furthermore, the cases came
fromdifferingsources (eg, individual cases, largekindreds, and
brainbanks).Theclinicaldataacquired in thestudywerebased
on retrospective reports by the patients, caregivers, and/or
treating physician. The nature of this study precluded stan-
dardized clinical assessments, which is a significant limita-
tion. An additional limitation includes the potential for false-
positive findingsdue tomultiple comparisons.Regardless, our
observations raise the hypothesis that LB pathology may be
the underlying basis for cognitive dysfunction in LRRK2 dis-
ease while at the same time being amarker for a broader par-
kinsonian symptom complex in LRRK2-related PD. This can
be tested in future prospective cohort studies of patientswith
LRRK2mutations.
An important unresolved question is: why are LBs absent
in a subset of patientswithLRRK2-relatedPD?The largenum-
ber of cases reported from various centers demonstrates that
LB-negative LRRK2-related PD is not an anomalous finding.
Genotype cannot account for this finding because the subset
of patientswithout LBs is not representedby 1 specificLRRK2
mutation. The possibility that LRRK2-related PD represents a
distinct disease from sporadic PD and thus can present with
non-LB pathology is unlikely based on the significant clinical
similarities betweenPDassociatedwithLRRK2mutations and
Table 4. Clinical Correlates of LB Pathology in LRRK2-Associated Parkinson Diseasea,b
Feature
All LRRK2 Cases
(N = 37)
LRRK2 p.G2019S Cases
(n = 17)
OR (95% CI) P Value OR (95% CI) P Value
Motor features
Bradykinesia 0.95 (0.05-17.97) .97 2.49 (0.08-80.81) .61
Rigidity 1.22 (0.06-26.80) .90 1.94 (0.07-53.77) .69
Tremor 1.03 (0.04-26.52) .99 0.60 (0.04-9.19) .71
Postural instability 2.22 (0.16-30.44) .55 4.55 (0.23-89.65) .32
Atypical features 0.54 (0.05-6.19) .62 1.38 (0.08-25.39) .83
Nonmotor features
Cognitive impairment/dementia 9.74 (1.80-52.60) .008 85.64 (1.52-4817.27) .03
Depression 3.06 (0.36-26.07) .31 3.33 (0.06-184.51) .56
Anxiety 17.87 (1.37-233.28) .03 24.69 (1.14-536.51) .04
Orthostatic hypotension 12.03 (1.17-123.93) .04 4.35 (0.31-61.10) .28
Urinary symptoms 2.25 (0.29-17.46) .44 6.82 (0.36-130.83) .20
Constipation 14.49 (0.78-267.71) .07 1.95 (0.06-68.51) .71
Levodopa treatment
Positive response 0.11 (0.01-2.42) .16 0.10 (0-3.21) .19
Fluctuations 0.10 (0.01-1.53) .10 0.14 (0.01-3.31) .22
Dyskinesia 0.31 (0.02-4.72) .40 0.92 (0.05-16.14) .95
Abbreviations: LB, Lewy body;
LRRK2, leucine-rich repeat kinase 2;
OR, odds ratio.
a Adjusted for disease duration and
age at death.
b The results for the features in bold
are statistically significant.
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sporadic PD,6 evidence from genome-wide association stud-
iesdemonstrating thatLRRK2polymorphismsare genetic risk
factors for sporadic PD,18 and experimental findings that im-
plicate the LRRK2 protein in molecular pathways underlying
PDpathogenesis.2Whileour studydidnot explainwhyLBsare
sometimes absent in LRRK2-related PD, it contributes to the
accumulating evidence that LBs alone cannot explain the
pathogenesis of PD but other forms of α-synuclein may also
play important roles.19 Indeed, small solubleaggregatesofα-sy-
nuclein have been isolated from the cortex of a patient with
G2019S LRRK2 PDwithout LBs.20 Our study also supports the
ongoing effort to reevaluate the pathological criteria used to
definePD, inparticular, deemphasizingLBsas a core feature.21
Conclusions
Lewybodypathology isnotpresent inall patientswithLRRK2-
related PD. Themutation p.G2019S ismore frequently associ-
ated with LB pathology compared with other LRRK2 muta-
tions. The classic parkinsonian motor symptoms can occur
without LBs, and a primarily motor phenotype appears to be
associated with an absence of LBs. The expression of certain
nonmotor features, particularly cognitive impairment, anxi-
ety, and orthostatic hypotension, is related to the presence of
LBs. Thus, LBpathology inLRRK2-relatedPDmaybeamarker
for a broader parkinsonian symptom complex.
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